GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (NYSE:PRGO) » Definitions » ROE %

Perrigo Co (Perrigo Co) ROE %

: -2.72% (As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Perrigo Co's annualized net income for the quarter that ended in Dec. 2023 was $-129 Mil. Perrigo Co's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $4,753 Mil. Therefore, Perrigo Co's annualized ROE % for the quarter that ended in Dec. 2023 was -2.72%.

The historical rank and industry rank for Perrigo Co's ROE % or its related term are showing as below:

PRGO' s ROE % Range Over the Past 10 Years
Min: -48.18   Med: 0.57   Max: 4.22
Current: -0.26

During the past 13 years, Perrigo Co's highest ROE % was 4.22%. The lowest was -48.18%. And the median was 0.57%.

PRGO's ROE % is ranked worse than
62.2% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.435 vs PRGO: -0.26

Perrigo Co ROE % Historical Data

The historical data trend for Perrigo Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 -2.84 -1.28 -2.81 -0.26

Perrigo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.01 -0.25 0.69 1.18 -2.72

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perrigo Co ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's ROE % distribution charts can be found below:

* The bar in red indicates where Perrigo Co's ROE % falls into.



Perrigo Co ROE % Calculation

Perrigo Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-12.7/( (4842.1+4767.9)/ 2 )
=-12.7/4805
=-0.26 %

Perrigo Co's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-129.2/( (4738.1+4767.9)/ 2 )
=-129.2/4753
=-2.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Perrigo Co  (NYSE:PRGO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-129.2/4753
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-129.2 / 4627.6)*(4627.6 / 10783.7)*(10783.7 / 4753)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2.79 %*0.4291*2.2688
=ROA %*Equity Multiplier
=-1.2 %*2.2688
=-2.72 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-129.2/4753
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-129.2 / -217.2) * (-217.2 / 363.6) * (363.6 / 4627.6) * (4627.6 / 10783.7) * (10783.7 / 4753)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.5948 * -0.5974 * 7.86 % * 0.4291 * 2.2688
=-2.72 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Perrigo Co ROE % Related Terms

Thank you for viewing the detailed overview of Perrigo Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Perrigo Co (Perrigo Co) Business Description

Traded in Other Exchanges
Address
The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Executives
Robert Willis officer: Acting CHRO C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Alison Ives officer: EVP & Chief Scientific Officer C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Eduardo Guarita Bezerra officer: EVP & Chief Financial Officer C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134
Patrick Lockwood-taylor director, officer: CEO C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503
Julia M Brown director C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001
Triona Schmelter officer: EVP & President CSCA 2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Svend Andersen director C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Murray S Kessler director, officer: CEO 714 GREEN VALLEY ROAD, GREENSBORO NC 27408
Thomas Farrington officer: Senior VP and CIO 4012 W. CANTERBURY CT., NEQUON WI 53092
Dillard James E Iii officer: EVP, Chief Scientific Officer 6601 WEST BROAD STREET, RICHMOND VA 23230
Ronald Craig Janish officer: EVP, Global Op. & Supply Chain PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Grainne Quinn officer: EVP, Chief Medical Officer PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Albert Manzone director C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000
Kyle Hanson officer: EVP & General Counsel